FDA grants orphan drug designation to vTv's HPPD for sickle cell disease
vTv Therapeutics announced that the U.S. Food and Drug Administration awarded orphan drug designation to its oral Nrf2/Bach1 modulator HPPD for sickle cell disease. The company said pre‑clinical work in a mouse model showed the drug raises fetal hemoglobin and lowers oxidative stress and red‑cell sickling, with results comparable to or better than hydroxyurea. The CEO noted the status could help the firm pursue partnership discussions while it continues to develop its diabetes candidate cadisegliatin, which holds Breakthrough Therapy designation. The announcement was made on 7 October 2026.
Why it matters
According to the CEO, the orphan designation may provide tax credits and grant incentives that improve the economics of HPPD’s development and make the program more attractive to partners. The designation does not change the regulatory timeline but could accelerate funding and collaboration for the sickle cell program.
Key facts
- 1The FDA granted orphan drug designation to HPPD (HPP8668) for sickle cell disease. globenewswire.com
- 2HPPD is an oral, first‑in‑class Nrf2/Bach1 modulator under investigation by vTv Therapeutics. globenewswire.com
- 3Preclinical studies in the Townes sickle cell mouse model showed dose‑dependent induction of fetal hemoglobin and reductions in oxidative stress and sickled red blood cells, with effects comparable to or exceeding hydroxyurea. globenewswire.com
- 4CEO Paul Sekhri said the designation strengthens vTv’s ability to discuss strategic partnerships for HPPD. globenewswire.com
- 5The press release announcing the designation was issued on Oct. 7 2026. globenewswire.com
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.